A Canadian biotechnology company developing the next generation of evidence-based psychedelic and cannabinoid therapeutics. With four licenses from Health Canada, including a Controlled Substance Dealer License, we are at the forefront of mental health and neurological treatment innovation.
Psilobrain Therapeutics is a Canadian biotechnology company dedicated to developing next-generation, evidence-based psychedelic and cannabinoid therapeutics. By leveraging recent scientific breakthroughs, we create products with a measurable impact on mental health and neurological conditions. Our work is supported by four licenses from Health Canada, including a Controlled Substance Dealer License, and we are authorized to distribute Psilocybin to patients in need through the Special Access Program (SAP).
As a leading provider of Psychedelic and Cannabinoid Active Pharmaceutical Ingredients (APIs), we are unlocking the global potential of these compounds. We supply pharmaceutical-grade controlled substances and cannabis isolates to leading organizations worldwide.
Our management team consists of serial entrepreneurs and industry veterans with a proven track record in the biotechnology and pharmaceutical sectors. Their expertise guides our strategic direction and has led to significant achievements, including establishing Brazil's first registered medical cannabis product.
Through our wholly-owned subsidiary, Vitality CBD, we are the #1 CBD brand in the UK. With over 50 cannabinoid SKUs and novel foods approved active ingredients, we are expanding our market presence into Spain, Portugal, Germany, and Italy.
Psilobrain is committed to a robust Drug Development Program, with two provisional patents and one PCT application entering the National Phase. We have achieved proof-of-concept for two drugs and are conducting three preclinical trials using psychedelic and cannabinoid APIs. Our focus on an integrated psychedelic-assisted therapy model is a novel approach in the industry.
We have established clinical partnerships representing over 5,500 patients seeking Psychedelic Therapy with Evidence-Based Counseling. By working closely with our partners, we deliver comprehensive solutions that meet the unique needs of the market and accelerate the development of new treatments.
Our management and advisory teams are industry veterans in the pharmaceutical and consumer goods industries. Members of our team have held C-suite and other senior positions within companies around the globe, bringing a wealth of experience to our operations.
Lorem ipsum dolor sit amet consecte adipiscing elit amet hendrerit pretium nulla sed enim iaculis mi.
Lorem ipsum dolor sit amet consecte adipiscing elit amet hendrerit pretium nulla sed enim iaculis mi.
Lorem ipsum dolor sit amet consecte adipiscing elit amet hendrerit pretium nulla sed enim iaculis mi.
Lorem ipsum dolor sit amet consecte adipiscing elit amet hendrerit pretium nulla sed enim iaculis mi.
Of Combined experience in industry specific sectors
Pharma Business Development Exp.
Retail and Distribution Experience
Health and Wellness Experience
Marketing Industry Experience
Psilobrain holds four licenses from Health Canada: a Cannabis Research License, an Analytical Testing License, a Processing License, and a Controlled Substance Dealer License. This comprehensive licensing allows for the research, development, possession, and distribution of psilocybin, psilocin, ketamine, DMT, and MDMA.
We have two provisional patents and one PCT application entering the National Phase, with a focus on Composition of Matter claims. One PCT filing may qualify for Orphan Drug Status.
We are a provider of Psychedelic and Cannabinoid Active Pharmaceutical Ingredients (APIs) and formulated drug products for the pharmaceutical sector, with established global supply agreements.
We are planning Investigator-Initiated Trials using Psilobrain products and are focused on an integrated psychedelic-assisted therapy model, which is a novel approach in the industry.
Targeting a significant global health issue affecting an estimated 10 million people annually.
Addressing a critical oncology indication with a market size opportunity of over $45 billion.
Developing treatments for a condition that is estimated to impact 22% of the population.
Our strategy includes securing Orphan Drug Status to curtail the development cycle, utilizing existing data to boost the likelihood of clinical success, and retaining ownership of our CMC Data package. This approach enhances the probability of successful commercialization and guarantees market protection for our drugs.
Our team has put together a comprehensive overview of our operations, highlighting our competitive advantages and market opportunities. Download our investor presentation to learn more about how we are pioneering the future of mental wellness.
